Global CD34+ Cell Selection Equipment Market Strategic Research Report

Scope of the Report

The global CD34+ Cell Selection Equipment market size is predicted to grow from US$ 80.73 million in 2025 to US$ 149 million in 2032; it is expected to grow at a CAGR of 9.0% from 2026 to 2032.

CD34+ cell selection equipment refers to instruments used to perform the separation, enrichment, or selection of CD34+ hematopoietic stem and progenitor cells. The core function of this type of equipment is to obtain enriched CD34+ cell populations from complex samples such as bone marrow, cord blood, mobilized peripheral blood, leukapheresis products, or PBMCs through hardware-based processes including anti-CD34 labeling systems, magnetic separation, column-based separation, column-free separation, or bag-based magnetic separation.

From an industrial positioning perspective, CD34+ cell selection equipment is located at the intersection of life science instruments, cell therapy manufacturing equipment, and hematopoietic stem cell transplantation support equipment. Its main uses include clinical graft processing, research-grade CD34+ cell separation, cell therapy process development, sample processing before gene editing, and GMP-grade cell preparation workflows. Technological development is moving from early manual magnetic racks and open manual operations toward closed, automated, traceable, high-throughput, and GMP-compatible equipment systems. In the current market, the number of equipment suppliers is significantly smaller than the number of reagent and consumable suppliers. Global equipment supply is mainly concentrated among Miltenyi Biotec, STEMCELL Technologies, Applied Cells, and a small number of magnetic separation device suppliers. Compared with kits and magnetic beads, the equipment market is smaller in scale and has lower purchase frequency, but the value per unit is higher, customer validation cycles are longer, and barriers to entry are also higher. The upstream segment of this type of equipment mainly includes magnet components, precision pumps and valves, fluidic control modules, sensors, touchscreens and embedded control systems, disposable tubing adaptation structures, electromechanical integrated components, quality management systems, and GMP validation capabilities. The reliability of upstream equipment directly affects cell recovery rate, cell viability, batch-to-batch consistency, sterility assurance, and process traceability. Downstream customers mainly include hematopoietic stem cell transplantation centers, hematology and oncology departments, cell therapy companies, gene-editing therapy companies, cell process development laboratories, CROs, CDMOs, and large research institutions. Downstream demand is not equivalent to the total number of hematopoietic stem cell transplantations, because only some transplantation and cell therapy workflows require CD34+ cell selection equipment. Nevertheless, HCT and cell therapy activities still form an important demand base. The EBMT report shows that HCT activity in Europe and surrounding regions reached 47,731 cases in 2023, with allogeneic HCT increasing by 7.8% year on year and CAR-T therapy increasing by 52.5%, indicating that transplantation and advanced cell therapy activities are still expanding. In terms of policy, the U.S. FDA has approved the CliniMACS CD34 Reagent System for specific AML patient settings, and gene therapy products based on enriched CD34+ cell populations, such as CASGEVY, have also been approved. These developments are increasing the importance of clinical-grade, closed, and verifiable cell processing equipment. Future trends in pricing, production volume, and market size will differ from those of reagents and consumables. Equipment prices are unlikely to decline rapidly like ordinary consumables, because their value mainly comes from hardware reliability, software control, closed processing workflows, GMP compatibility, after-sales service, validation documentation, and customer process lock-in. However, research-grade automated separators and semi-automated magnetic separation devices may experience gradual unit price declines due to intensified competition and domestic substitution. In terms of production volume, annual shipments of clinical-grade closed equipment will continue to show the characteristics of small batches and high unit prices, while shipments of research-grade automation equipment and process development equipment are expected to grow faster, mainly driven by cell therapy process development, CD34+ gene-editing research, and laboratory automation demand. This market is not a large-scale consumables market, but a small-scale, high-barrier specialized equipment market that is gradually expanding alongside the automation of cell therapy manufacturing.

Key Questions Addressed in this Report

What is the 10-year outlook for the global CD34+ Cell Selection Equipment market?

What factors are driving CD34+ Cell Selection Equipment market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do CD34+ Cell Selection Equipment market opportunities vary by end market size?

How does CD34+ Cell Selection Equipment break out by Technology Route, by Application?

This report presents a comprehensive overview of the global CD34+ Cell Selection Equipment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Technology Route

• Column-Based Immunomagnetic Selection
• Column-Free Immunomagnetic Selection
• Buoyancy-Activated Microbubble Sorting

Segment by Product Delivery Form

• Closed Clinical System
• Laboratory Selection Kit
• Platform-Based Selection Instrument

Segment by CD34+ Cell Acquisition Workflow

• Direct Positive Selection
• Direct Negative Enrichment
• Pre-Enrichment Followed By Positive Selection

Segment by Application

• Clinical Transplant Cell Preparation
• Research-Use Cell Isolation
• Process Development And Translational Research

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global CD34+ Cell Selection Equipment market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Clinical Transplant Cell Preparation, Research-Use Cell Isolation, Process Development And Translational Research evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact